Training on Systemic and Organ Spec. PM in PC

Impact of Prescribed Physical Training on Systemic and Organ Specific Prognostic Markers in Prostate Cancer

This research is being done to assess the impact of a supervised and structured strength and conditioning program on cardiac remodeling in participants with prostate cancer undergoing treatment with external beam radiation therapy and at least 6 months of Gonadotropin-releasing hormone (GnRH) therapy.

This study is designed to determine the impact of a strength and conditioning program on cardiac remodeling in participants with prostate cancer undergoing treatment with external beam radiation therapy and at least 6 months of Gonadotropin-releasing hormone (GnRH) therapy. In this study the participants will complete an exercise program that includes structured strength and conditioning programs which may include weightlifting, running, cycling, and stretching. During the research study participants will have data collected and blood samples taken which will be used to evaluate the prevention and reduction of potential harms induced by prostate cancer treatment. Participants will be in this research for 7 months which includes 6-months of the exercise intervention along with 1-month post-intervention activities. It is expected that about 20 people will take part in this research study.

Inclusion Criteria:

• Have histologically or cytologically confirmed adenocarcinoma of the prostate
• Have not received GnRH agonist or antagonist within the last 12 months
• Planned for initiation of a GnRH agonist or antagonist or bilateral orchiectomy with an intended treatment duration of ≥ 6 months
• Planned for initiation of radiation therapy to the prostate.
• ECOG performance status of 0 or 1
• Ability to understand and the willingness to sign a written informed consent document
• Baseline serum total testosterone level > 230 ng/dL (the accepted threshold for testosterone supplementation)
• Speak English ->18 years of age

Exclusion Criteria:

• Has a known medical condition that makes the subject unable to participate in exercise testing (e.g. unrevascularized coronary artery disease, moderate/severe osteoarthritis, prior stroke, or other conditions)
• Receiving or planned to receive other cancer therapy not included in Eligibility Criterion 3.1.3 (other than an antiandrogen during the first month of therapy)
• The following populations will not be considered for inclusion on this trial.